Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;63(14):3351-3361.
doi: 10.1080/10428194.2022.2131419. Epub 2022 Oct 18.

A prospective analysis of red blood cell membrane polyunsaturated fatty acid levels and risk of non-Hodgkin lymphoma

Affiliations

A prospective analysis of red blood cell membrane polyunsaturated fatty acid levels and risk of non-Hodgkin lymphoma

Andres V Ardisson Korat et al. Leuk Lymphoma. 2022 Dec.

Abstract

Published studies report inconsistent associations of polyunsaturated fatty acid (PUFA) intake with non-Hodgkin lymphoma (NHL) risk. We conducted a nested case-control study in Nurses' Health Study and Health Professionals Follow-Up Study participants to evaluate a hypothesis of inverse association of pre-diagnosis red blood cell (RBC) membrane PUFA levels with risk of NHL endpoints. We confirmed 583 NHL cases and matched 583 controls by cohort/sex, age, race and blood draw date/time. We estimated odds ratios (OR) and 95% confidence intervals (CI) for risk of NHL endpoints using logistic regression. RBC PUFA levels were not associated with all NHL risk; cis 20:2n-6 was associated with follicular lymphoma risk (OR [95% CI] per one standard deviation increase: 1.35 [1.03-1.77]), and the omega-6/omega-3 PUFA ratio was associated with diffuse large B-cell lymphoma risk (2.33 [1.23-4.43]). Overall, PUFA did not demonstrate a role in NHL etiology; the two unexpected positive associations lack clear biologic explanations.

Keywords: Red blood cell membrane fatty acids; epidemiology; etiology; non-Hodgkin lymphoma; polyunsaturated fatty acids; prospective.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement: SC is presently an employee at AbbVie, in which capacity she receives stock/stock options; SZ is presently an employee and holds restricted share units of Johnson & Johnson; neither SC nor SZ had competing interests or conflicts at the time the project was designed, funded and initiated. The remaining authors declare no potential competing interests or conflicts of interest.

References

    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375–2390. - PMC - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33. - PubMed
    1. Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer 2020;126:2225–2249. - PMC - PubMed
    1. Cerhan JR, Vajdic CM, Spinelli JJ. The Non-Hodgkin Lymphomas. In: Michael Thun, Linet Martha S., Cerhan James R., Haiman Christopher A., Schottenfeld D, editors. Cancer Epidemiology and Prevention. USA: Oxford University Press; 2017. p 767–796.
    1. Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:130–144. - PMC - PubMed

Substances

LinkOut - more resources